½ÃÀ庸°í¼­
»óǰÄÚµå
1666902

ÇコÄÉ¾î ºÐ¾ß ÀΰøÁö´É ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2024-2032³â)

Artificial Intelligence in Healthcare Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÇコÄÉ¾î ºÐ¾ß ÀΰøÁö´É ¼¼°è ½ÃÀåÀº 2024³â 187¾ï ´Þ·¯·Î Æò°¡µÇ¸ç 2025³âºÎÅÍ 2034³â±îÁö ¿¬Æò±Õ 37.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ÇコÄÉ¾î ¿¬±¸¿¡¼­ÀÇ AI Ȱ¿ë È®´ë, ´Ù¾çÇÑ ¾ÖÇø®ÄÉÀ̼ÇÀÇ ÃâÇö, À¯¸®ÇÑ ÀÚ±Ý Á¶´Þ ȯ°æ µîÀÔ´Ï´Ù. Áø´Ü Á¤È®µµ Çâ»ó, ÀÓ»ó ¿öÅ©Ç÷οì ÃÖÀûÈ­, Ä¡·á¹ý °³¹ß °¡¼ÓÈ­ µî AIÀÇ Çõ½ÅÀû ¿ªÇÒÀº AI¸¦ ÇコÄÉ¾î »ê¾÷¿¡¼­ Çõ½ÅÀÇ ÇÙ½ÉÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

Artificial Intelligence in Healthcare Market-IMG1

ÇコÄÉ¾î ºÐ¾ß ÀΰøÁö´É ½ÃÀåÀº ¼ÒÇÁÆ®¿þ¾î¿Í ¼­ºñ½º·Î ±¸ºÐµÇ¸ç, ¼ÒÇÁÆ®¿þ¾î ºÎ¹®Àº 2034³â±îÁö ¿¬Æò±Õ 36.9%ÀÇ ¼ºÀå·ü·Î 2,529¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. AI ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀº ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ ÀÇ»ç°áÁ¤À» °³¼±Çϰí, ¾÷¹«¸¦ °£¼ÒÈ­Çϸç, °³ÀÎÈ­µÈ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ÀÇ·á ¿µ»ó, ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ºÐ¼®, °¡»ó °Ç°­ µµ¿ì¹Ì¿Í °°Àº ÀÛ¾÷¿¡ ±â°è ÇнÀ(ML) ¹× ÀÚ¿¬¾î ó¸®(NLP) ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, SaaS(Software-as-a-Service) ¸ðµ¨ÀÇ È®À强°ú ºñ¿ë È¿À²¼ºÀº ±× ¸Å·ÂÀ» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2023³â
¿¹Ãø ¿¬µµ 2024-2032³â
½ÃÀÛ ±Ý¾× 187¾ï ´Þ·¯
¿¹»ó ±Ý¾× 3,171¾ï ´Þ·¯
CAGR 37.1%

´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß Áß ÀÇ·á ¿µ»ó ¹× Áø´Ü ºÐ¾ß°¡ 2024³â 74¾ï ´Þ·¯ÀÇ ¼öÀÍÀ» âÃâÇÏ´Â ÁÖ¿ä ºÎ¹®À¸·Î ºÎ»óÇß½À´Ï´Ù. ÀÌ ºÎ¹®Àº ¹æ´ëÇÑ À̹ÌÁö µ¥ÀÌÅͼ¼Æ®¸¦ ºÐ¼®Çϰí, ÀÌ»óÀ» °¨ÁöÇϰí, Ź¿ùÇÑ Á¤È®µµ·Î ÆÐÅÏÀ» ½Äº°ÇÒ ¼ö ÀÖ´Â AIÀÇ ´É·ÂÀ¸·Î ÀÌÀÍÀ» ¾ò°í ÀÖ½À´Ï´Ù. AI ±â¹Ý µµ±¸´Â Áø´Ü Á¤È®µµ¸¦ ³ôÀÌ°í ¹æ»ç¼±°ú ÀÇ»çÀÇ ¾÷¹« ºÎ´ãÀ» ÁÙÀÓÀ¸·Î½á Çö´ë ÀÇ·á ½Ã½ºÅÛ¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

ºÏ¹Ì ÇコÄɾî ÀΰøÁö´É ½ÃÀåÀº 2024³â 77¾ï ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇßÀ¸¸ç, 2025-2034³â±îÁö ¿¬Æò±Õ 37.7%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ¿ìÀ§´Â ÷´Ü ±â¼ú ÀÎÇÁ¶ó, ³ôÀº ÀÇ·áºñ ÁöÃâ, Áö¿øÀûÀÎ ±ÔÁ¦ Á¤Ã¥¿¡ ±âÀÎÇÕ´Ï´Ù. Áø´Ü, ÀǾàǰ °³¹ß, º´¿ø ¿öÅ©Ç÷οì ÃÖÀûÈ­¿Í °°Àº Çõ½ÅÀûÀÎ ±â¼úÀÇ Á¶±â µµÀÔÀ¸·Î ºÏ¹Ì´Â ¼¼°è AI ÇコÄÉ¾î ½ÃÀå¿¡¼­ È®°íÇÑ ¸®´õ½ÊÀ» È®º¸Çϰí ÀÖ½À´Ï´Ù.

AI°¡ °è¼Ó ÁøÈ­Çϸ鼭 ÇコÄÉ¾î ºÐ¾ß¿¡¼­ÀÇ Àû¿ë ¹üÀ§°¡ È®´ëµÇ°í ÀÖÀ¸¸ç, Áø´Ü, ¸ÂÃãÇü ÀÇ·á, ¾÷¹« È¿À²È­¿¡ ÀÖ¾î Àü·Ê ¾ø´Â ÁøÀüÀ» ÀÌ·ê ¼ö ÀÖ´Â ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀå ±ËÀûÀº ¼¼°è ÇコÄɾîÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â µ¥ ÀÖ¾î AI°¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¿¬±¸ ºÐ¾ßÀÇ ÇコÄɾî ÀΰøÁö´É ä¿ë Áõ°¡
      • ÇâÈÄ ÀÀ¿ë ¹üÀ§ È®´ë
      • ºòµ¥ÀÌÅÍ ºÐ¼®ÀÇ Áøº¸
      • À¯¸®ÇÑ ÀÚ±Ý Á¶´Þ ½Ã³ª¸®¿À
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
      • ³ôÀº Ãʱâ ÀÚº» ¿ä°Ç
      • ȯÀÚ µ¥ÀÌÅÍ¿¡ °üÇÑ º¸¾È»ó ¿ì·Á
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ƯÇ㠺м®
  • ½ºÅ¸Æ®¾÷ ½Ã³ª¸®¿À
  • ÇコÄÉ¾î ºÐ¾ß ÀΰøÁö´É ÇÁ·ÎÁ§Æ®
  • ÀÇ·á¿Í ±â¼úÀÇ Áøº¸
  • ±ÔÁ¦ »óȲ
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • Porters ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Á¦°øº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¼ÒÇÁÆ®¿þ¾î
  • ¼­ºñ½º

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ÀÇ·á¿ë ¿µ»ó Áø´Ü
  • Drug Discovery
  • ¿öÅ©ÇÃ·Î¿ì °ü¸®
  • ȯÀÚ Âü¿© ¼Ö·ç¼Ç
  • »çÀ̹ö º¸¾È
  • ±âŸ ¿ëµµ

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ÀÇ·á Á¦°øÀÚ
    • º´¿ø ¹× Áø·á¼Ò
    • Áø´Ü ¼¾ÅÍ
    • ±âŸ ÀÇ·á Á¦°øÀÚ
  • Á¦¾à¡¤»ý¸í°úÇÐ ±â¾÷
  • ÇコÄɾî ÁöºÒÀÚ

Á¦8Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®

Á¦9Àå ±â¾÷ °³¿ä

  • AiCure
  • Aidoc
  • Apixio
  • Dassault Systemes(Medidata)
  • Enlitic
  • Insilico Medicine
  • International Business Machines
  • IQVIA
  • Itrex Group
  • Koninklijke Philips N.V.
  • Microsoft
  • NVIDIA
  • Persistent Systems
  • Siemens Healthineers
  • Sophia Genetics
ksm 25.03.31

The Global Artificial Intelligence In Healthcare Market was valued at USD 18.7 billion in 2024 and is projected to grow at a CAGR of 37.1% from 2025 to 2034. Key factors driving this growth include the expanding use of AI in healthcare research, the emergence of diverse applications, and favorable funding environments. The transformative role of AI in enhancing diagnostic accuracy, optimizing clinical workflows, and expediting treatment development has positioned it as a cornerstone of innovation in the healthcare industry.

Artificial Intelligence in Healthcare Market - IMG1

Artificial intelligence in healthcare market is segmented into software and services, with the software category growing at a CAGR of 36.9% and generating USD 252.9 billion through 2034. AI software solutions enable healthcare providers to improve decision-making, streamline operations, and offer personalized care. Increased adoption of machine learning (ML) and natural language processing (NLP) technologies for tasks such as medical imaging, electronic health record (EHR) analysis, and virtual health assistants is fueling demand. Additionally, the scalability and cost-efficiency of software-as-a-service (SaaS) models further enhance the appeal.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$18.7 Billion
Forecast Value$317.1 Billion
CAGR37.1%

Among various applications, medical imaging and diagnosis emerged as a leading segment in 2024, generating USD 7.4 billion in revenue. This segment benefits from AI's ability to analyze vast imaging datasets, detect anomalies, and identify patterns with unmatched precision. By improving diagnostic accuracy and reducing radiologists' workload, AI-powered tools are becoming indispensable in modern healthcare systems.

North America artificial intelligence in healthcare market generated USD 7.7 billion in 2024 and is forecasted to grow at a CAGR of 37.7% from 2025 to 2034. The region's dominance can be attributed to advanced technological infrastructure, significant healthcare spending, and supportive regulatory policies. Early adoption of innovative technologies across diagnostics, drug development, and hospital workflow optimization has solidified North America's leadership in the global AI healthcare market.

As AI continues to evolve, its applications in healthcare are broadening, paving the way for unprecedented advancements in diagnostics, personalized medicine, and operational efficiency. The market's growth trajectory highlights its critical role in shaping the future of healthcare globally.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising adoption of healthcare artificial intelligence in research areas
      • 3.2.1.2 Increasing range of future applications
      • 3.2.1.3 Advancements in big data analytics
      • 3.2.1.4 Favorable funding scenario
    • 3.2.2 Industry pitfalls AND challenges
      • 3.2.2.1 High initial capital requirement
      • 3.2.2.2 Security concerns regarding patient data
  • 3.3 Growth potential analysis
  • 3.4 Patent analysis
  • 3.5 Start-up scenario
  • 3.6 Artificial intelligence in healthcare projects
  • 3.7 Medical and technological advancements
  • 3.8 Regulatory landscape
  • 3.9 Future market trends
  • 3.10 Porter’s analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Offering, 2021 – 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Software
  • 5.3 Services

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Medical imaging and diagnosis
  • 6.3 Drug discovery
  • 6.4 Workflow management
  • 6.5 Patient engagement solutions
  • 6.6 Cybersecurity
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Healthcare providers
    • 7.2.1 Hospitals and clinics
    • 7.2.2 Diagnostic centers
    • 7.2.3 Other healthcare providers
  • 7.3 Pharmaceutical and life sciences companies
  • 7.4 Healthcare payors

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 AiCure
  • 9.2 Aidoc
  • 9.3 Apixio
  • 9.4 Dassault Systemes (Medidata)
  • 9.5 Enlitic
  • 9.6 Insilico Medicine
  • 9.7 International Business Machines
  • 9.8 IQVIA
  • 9.9 Itrex Group
  • 9.10 Koninklijke Philips N.V.
  • 9.11 Microsoft
  • 9.12 NVIDIA
  • 9.13 Persistent Systems
  • 9.14 Siemens Healthineers
  • 9.15 Sophia Genetics
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦